Literature DB >> 1686206

Evidence against a role for dopamine D1 receptors in the myocardium of the pig.

L J Van Woerkens1, D J Duncker, M O Den Boer, E O McFalls, L M Sassen, P R Saxena, P D Verdouw.   

Abstract

1. We investigated the presence of dopamine D1 receptors in the myocardium of anesthetized pigs using intravenous infusions of dopamine, alone and after alpha- and beta-adrenoceptor blockade and intracoronary infusions of the selective D1 receptor agonist, fenoldopam. 2. Intravenous infusion of dopamine (2.5, 5 and 10 micrograms kg-1 min-1 for 10 min, n = 6) caused dose-dependent changes in heart rate (from 94 +/- 6 to 132 +/- 10 beats min-1, P less than 0.05), the maximal rate of rise of left ventricular pressure (LVdP/dtmax; from 2280 +/- 170 to 4800 +/- 410 mmHgs-1, P less than 0.05), mean arterial blood pressure (from 87 +/- 5 to 62 +/- 3 mmHg) and systemic vascular resistance (from 40 +/- 4 to 28 +/- 2 mmHgl-1 min, P less than 0.05). The increases in heart rate and LVdP/dtmax were abolished when dopamine was infused after alpha- and beta-adrenoceptor blockade. The vasodilator response was, however, only minimally affected. 3. Intravenous infusions of dopamine decreased coronary vascular resistance from 0.90 +/- 0.06 to 0.53 +/- 0.07 mmHg ml-1 min 100 g (P less than 0.05). This action of dopamine was not observed when dopamine was infused after blockade of the alpha- and beta-adrenoceptors. 4. Pretreatment with alpha- and beta-adrenoceptor blockade had no effect or only slightly attenuated the dopamine-induced decrease in vascular resistance of the brain, kidneys, adrenals and small intestine. 5. In 7 animals, intracoronary doses of 0.04, 0.1, 0.2 and 0.4g kg1- min 1 of fenoldopam had no effect on coronary venous oxygen content, local myocardial oxygen consumption, coronary blood flow or coronary vascular resistance. However, systemic effects were observed at the highest two doses, as manifested by a drop in mean arterial blood pressure from 82 +/- 4 to 72 +/- 4mmHg (P < 0.05) due to peripheral vasodilatation (e.g. cerebral vascular bed). Heart rate, LVdP/dt,.,, regional myocardial segment length shortening and left ventricular end-diastolic pressure were not affected at these doses. In 2 animals the infusion rate was increased to 4jug kg1 min 1, but again there was no evidence for coronary vasodilatation. 6. We conclude that the intravenous infusion of dopamine after alpha- and beta-adrenoceptor blockade and the intracoronary infusion of fenoldopam provided no evidence for a major role of D1 receptors in the coronary circulation of pigs. The absence of any effect of the employed doses of fenoldopam on LVdP/dt.mx and on regional myocardial segment length shortening also indicates that fenoldopam does not exhibit any inotropic action in this species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686206      PMCID: PMC1908288          DOI: 10.1111/j.1476-5381.1991.tb12414.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs.

Authors:  P D Verdouw; L M Sassen; D J Duncker; I O Schmeets; R J Rensen; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

2.  Azaperone, a sedative neuroleptic of the butyrophenone series with pronounced anti-aggressive and anti-shock activity in animals.

Authors:  C J Niemegeers; J M Van Nueten; P A Janssen
Journal:  Arzneimittelforschung       Date:  1974-11

3.  Usefulness of pimobendan in the treatment of heart failure.

Authors:  D J Duncker; F J van Dalen; J M Hartog; J M Lamers; R J Rensen; P R Saxena; P D Verdouw
Journal:  Arzneimittelforschung       Date:  1986-12

4.  Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries.

Authors:  A D Hughes; P S Sever
Journal:  Blood Vessels       Date:  1989

5.  Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog.

Authors:  G A Kopia; R E Valocik
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

6.  Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.

Authors:  J P Hieble; D A Owen; C A Harvey; A L Blumberg; R E Valocik; R M DeMarinis
Journal:  Clin Exp Hypertens A       Date:  1987

7.  In vitro evidence for dopaminergic receptors in human renal artery.

Authors:  S Ueda; S Yano; M Sakanashi
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

8.  Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics.

Authors:  R R Zhao; W H Fennell; F L Abel
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

9.  The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs.

Authors:  L M Sassen; L K Soei; M M Koning; P D Verdouw
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

10.  Dopamine vasodilates human cerebral artery.

Authors:  N Toda
Journal:  Experientia       Date:  1983-10-15
View more
  3 in total

1.  Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade.

Authors:  L J van Woerkens; F Boomsma; A J Man in 't Veld; M M Bevers; P D Verdouw
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

2.  Effects of acute beta-adrenoceptor blockade with metoprolol on the renal response to dopamine in normal humans.

Authors:  N V Olsen; T Lang-Jensen; J M Hansen; I Plum; J K Thomsen; S Strandgaard; P P Leyssac
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

3.  Possible involvement of NMDA receptor-mediated transmission in barbiturate physical dependence.

Authors:  M Rabbani; J Wright; A R Butterworth; Q Zhou; H J Little
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.